Overview

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Status:
Active, not recruiting
Trial end date:
2035-07-01
Target enrollment:
Participant gender:
Summary
Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.
Phase:
Phase 1
Details
Lead Sponsor:
Bellicum Pharmaceuticals